Citizens JMP analyst Roy Buchanan raised the firm’s price target on Enanta (ENTA) to $24 from $23 and keeps an Outperform rating on the shares. Enanta remains on track to report Phase 2 results for oral RSV therapeutic candidate zelicapavir in Q3, but has indicated that further development of it and RSV-polymerase inhibitor EDP-323 will be dependent on a partner, the analyst tells investors in a research note. The firm has removed RSV from its valuation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: